医药生物行业快评报告：医保支持真创新，促进创新药产业发展

Investment Rating - The industry investment rating is "stronger than the market," indicating an expected relative increase of over 10% in the industry index compared to the broader market within the next six months [9]. Core Insights - The report emphasizes that the National Medical Insurance Administration (NMIA) will promote high-quality development in the pharmaceutical and biotechnology industry through various measures, including optimizing payment settlement mechanisms and supporting the development of commercial health insurance [2][3]. Summary by Sections Investment Highlights - The NMIA has included 949 new drugs in the medical insurance catalog, bringing the total to 3,253 drugs. Future plans include the release of a new version of the disease-based payment grouping scheme and the implementation of quarterly or monthly special case reviews to support the clinical use of new drugs and technologies [3]. - The NMIA has established a commercial health insurance innovative drug catalog, which includes 19 drugs with significant clinical value and innovation. This aims to encourage the integration of commercial health insurance with basic medical insurance and promote investment in innovative drug development [3][4]. - The NMIA will support differentiated innovation in the pharmaceutical industry and enhance the multi-channel payment capabilities for innovative drugs. This includes conducting new rounds of national drug procurement and expanding direct settlement for selected drugs and consumables [4]. - The NMIA plans to accelerate the construction of a national health insurance digital platform and explore a comprehensive value evaluation system for health insurance, which will enhance the participation of various stakeholders in the healthcare ecosystem [4].